Blue Water Vaccines, Inc. (BWV) Research

Blue Water Vaccines, Inc. (BWV) operates as a biotechnology firm dedicated to the worldwide discovery and development of vaccines aimed at preventing infectious diseases. Currently in preclinical stages, their most prominent vaccine candidates are BWV-101, an influenza shot, and BWV-102, designed to counter H1 pre-pandemic threats. The company's developmental portfolio also includes other preclinical programs such as BWV-201, a vaccine addressing acute otitis media caused by Streptococcus pneumoniae; BWV-301, a combined vaccine for norovirus and rotavirus; and BWV-302, a dual-target vaccine for norovirus and malaria. Founded in 2018, BWV's operations are based in Cincinnati, Ohio.

Market snapshot

Symbol
BWV
Price
$0.18
Day change
-6.97%
Market cap
$315.3K
P/E ratio
-0.06x
52-week range
0.1601-1.95
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$4.00

Peer companies

  • Affimed N.V. (AFMD)
  • AzurRx BioPharma, Inc. (AZRX)
  • Atreca, Inc. (BCEL)
  • Gritstone bio, Inc. (GRTS)
  • Idera Pharmaceuticals, Inc. (IDRA)
  • Lisata Therapeutics, Inc. (LSTA)
  • Q32 Bio Inc. (QTTB)
  • RVL Pharmaceuticals plc (RVLP)

Recent insider activity

  • Schiess Ralph — trade (0 shares) on 2023-12-15
  • Bruhlmann Christian — trade (0 shares) on 2023-12-15
  • CAMPBELL NEIL J — trade (532326 shares) on 2023-10-04
  • Harmon Bruce — trade (177442 shares) on 2023-10-04
  • Jeremic Vuk — A-Award (6360 shares) on 2023-05-31

Open Blue Water Vaccines, Inc. (BWV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.